La chaîne d'options affiche les données clés des options sur actions de Bristol-Myers Squibb à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Bristol-Myers Squibb..

Bristol-Myers Squibb (OTC:BMYMP) Stock, Chaîne d'Options

Bristol-Myers Squibb

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

BRISTOL-MYERS SQUIBB $2PR by Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co

<a href="https://www.bloomberg.com/news/articles/2025-07-16/tesla-failed-to-stop-autopilot-misuse-safety-expert-testifies">https://www.bloomberg.com/news/articles/2025-07-16/tesla-failed-to-stop-autopilot-misuse-safety-expert-testifies</a>

News

General

TSLA

'Tesla Failed to Stop Autopilot Misuse, Safety Expert Testifies'- Bloomberg

Biotech

FBIO

Fortress Biotech Reveals AstraZeneca's Anselamimab Trial Did Not Achieve Statistical Significance

Watts Water Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTS#NYSE">WTS</a>) has outperformed the market over the past 20 years by 1.69% on an annualized basis producing an average annual return of 10.15%. Currently, Watts Water Technologies has a market capitalization of $8.24 billion. 
Buying $1000 In WTS: If an investor had bought $1000 of WTS stock 20 years ago, it would be worth $6,950.48 today based on a price of $247.02 for WTS at the time of writing.
<h3>Watts Water Technologies's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752701420_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In Watts Water Technologies 20 Years Ago Would Be Worth This Much Today

MOCKSVILLE, N.C., July 16, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction is creating a new pathway to reducing the rate of smoking and related health harms through increasing adoption of its VLN&#xAE; reduced nicotine content cigarette products by additional brands. Our products incorporate proprietary and patented tobacco having 95% less nicotine than tobacco used in highly addictive conventional cigarettes. Decades of peer reviewed studies have shown that the level of nicotine content in 22nd Century's products can reduce both the rate of smoking and the health harms of smoking.
The recently announced partner VLN&#xAE; initiatives, such as Smoker Friendly VLN&#xAE;, Pinnacle VLN&#xAE;, reflect a growing commitment by tobacco brands to accelerate compliance with the U.S. Food and Drug Administration's proposed new <a href="https://www.globenewswire.com/Tracker?data=qlpGKAiiF5amDEZPNG9E1wa0Bx3dDtMM77VR4RbGJWSubkI9NnsX4N1cBnG6QdN_kUoNErrTFIBV7KXnUVtrBN6QnbLszIYZiP-IXRrNi4aZKKYUOwJXlHz20F14ZOUA4rq83ew202ivfMaQwgyfnbs7rflxFw73cB7OOmHanCVTsyNlxkQqi2Ay00DeHYTTwyYQ_Kj6P81tDgEi18eBilqqsUy3Cp81M4rSMJ4ZhIe5XYRnoe5ltraZ32_Hih3F">Tobacco Product Standard for Nicotine Yield of Cigarettes and Certain Other Combusted Tobacco Products</a>, which is intended to curb the harms of smoking.
"The FDA recognizes that nicotine is a highly addictive substance and that to achieve true tobacco harm reduction, nicotine consumption must be addressed. The FDA's new product standard proposed in January is one of many factors that are driving early commercial interest in our VLN reduced nicotine content tobacco products. We are excited to see our customer's brands adding VLN cigarettes to their lineup. This will enhance market availability of VLN cigarettes and offer customers a Tobacco Harm Reduction product that will give the smoker a choice to control their nicotine consumption," said Larry Firestone, Chief Executive Officer of 22nd Century Group. "These commercial launches and our readiness once we receive state approval to scale availability to all 50 states for the entire U.S. cigarette market continues to demonstrate that there need not be any commercial barriers to adopting this FDA policy, which could be the most impactful health decision in a generation."
Formally announced in January 2025, the proposed standard sets a maximum nicotine content of 0.7 mg of nicotine per gram of tobacco in cigarettes and certain other combusted tobacco products, taking effect two years from final approval. VLN&#xAE; based products from 22nd Century are the only combustible cigarette products authorized by the FDA to meet the standard, at an average of 0.5 mg per gram, and the only product that offers consumers a choice about their nicotine consumption.
On implementation of the FDA proposal, people who are addicted and wish to alter their dependency or even quit could have the ability to do so more easily, significantly reducing the morbidity and mortality caused by smoking. Based on FDA's population health model, by the year 2100, in the United States, approximately 48 million youth and young adults who would have otherwise initiated smoking would not start as a result of the proposed product standard.
22nd Century is monitoring comment submissions under the proposed rule and intends to make its own submission before the comment period closes.
This activity follows the 2018 rule making process, which ultimately incorporated many of the suggestions, independent clinical research studies and feasibility data from <a href="https://www.globenewswire.com/Tracker?data=hu5Ct19R2VxJK1gnvpGqpKi-1bjPVXLyYhiKAu_4DsP23n5DivM-Nbokt2G7wUqlRbM_EMgpddvZzLc2hVHmW655I4SF60Dlx5HKIPOR1MbBGl_BScadSFdFodZvABp9a5M3NwrNt2ZavMxeO6mawHW470JYY6bHFG3mGw3gBng=">22nd Century's comment letter at that time</a>, including:
<ul>
<li>A proposed standard of not more than 0.7mg/g of nicotine content, based on 22nd Century's recommendation of an average of 0.5mg/g,</li>
<li>The fact that our patented low nicotine content tobacco leaf contained in our VLN Products that already meets the standard can be readily sourced in enough quantity to meet demand for reduced nicotine content cigarette products, and</li>
<li>The fact the reduced nicotine content tobacco is an effective way to reduce the rate and harms of smoking, as documented by dozens of peer reviewed and published independent clinical studies using research cigarettes manufactured by 22nd Century &nbsp;</li>
</ul>
The <a href="https://www.globenewswire.com/Tracker?data=0Muji-qgH5MFNwCDVb86z3wLdp65rxkCvpIGpTpnNfIiwEfFZI8YdRDGe7JKTN_y7BNIAxpGiFJ_3i3Ovfxx35ZmAI1S_-iP-PMpFJVadmBBI5WcCjn4VWoTfpc1k3OK9MuYQNy9mpUOh-gLikypMsac4w8-ysu5Wu_FPebSjUml0znYBoH97FfzgN_mFcB8bqx1EZCXj3eXmfSywdZGvSk-bPPambpvRbGxO-FCE5LN-eQNXrjXDuTyShONIyHszhjR_aBNGKe8FHA8K8JkEca8MWYfhFeU6yL6WB5F1lvtZBOJ33ii_DAcZpVRau6QxS8hTxm_9lGGGk8cFHhwJT9WorjZ3UFxTNPROdVbZ-czEclwanfiP7Tjdih9VtWyP1gFni13VIaofKXo-Qmk1w==">FDA's January 15, 2025 press release</a> announcing the rule includes the following statement from the former FDA Commissioner Robert M. Califf, M.D.: "Today's proposal envisions a future where it would be less likely for young people to use cigarettes and more individuals who currently smoke could quit or switch to less harmful products. This action, if finalized, could save many lives and dramatically reduce the burden of severe illness and disability, while also saving huge amounts of money. I hope we can all agree that significantly reducing the leading cause of preventable death and disease in the U.S. is an admirable goal we should all work toward."

XXII

22nd Century Group Reveals Multiple Tobacco Brands Partnering With 22nd Century To Expand Availability and Awareness of VLN-Based Reduced Nicotine Content Products

Earnings

Union Bankshares Q2 EPS $0.53 Up From $0.45 YoY, Sales $13.200M Up From $12.300M YoY

Earnings Beats

HOMB

Home BancShares Q2 Adj. EPS $0.58 Beats $0.57 Estimate, Sales $271.000M Beat $262.560M Estimate

Western Alliance Bank To Unify All Divisions Under One Brand; AmeriHome Mortgage Unit & Its Affiliate Western Alliance Trust Company Will Continue With Their Current Names

MP Materials Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MP#NYSE">MP</a>) shares are trading lower in after-hours on Wednesday after the company announced a <a href="https://www.benzinga.com/pressreleases/25/07/b46455081/mp-materials-announces-commencement-of-proposed-500-million-public-offering-of-common-stock">proposed public offering</a>.
What Happened: MP Materials said it commenced a&nbsp;$500 million&nbsp;underwritten public offering of its common stock. The company expects to grant the underwriters a 30-day option to buy up to an additional&nbsp;15%&nbsp;of the shares sold in the offering.
All shares are being offered by MP Materials. The company intends to use the net proceeds to fund the acceleration and expansion of its operations and for strategic growth opportunities.
The offering comes after MP Materials shares hit all-time highs this week on the back of deals with the Department of Defense and Apple. 
MP Materials entered into a&nbsp;<a href="https://www.benzinga.com/news/contracts/25/07/46340107/mp-materials-gets-pentagon-boost-as-us-battles-china-for-rare-earths" target="_blank" rel="noreferrer noopener">public-private partnership</a>&nbsp;with the Department of Defense last week aimed at building out an end-to-end U.S. rare earth magnet supply chain to reduce foreign dependency. The company also announced a <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46414833/mp-materials-stock-surges-on-500-million-partnership-with-apple">long-term partnership</a> with Apple on Tuesday to supply the iPhone maker with magnets. Magnet shipments intended to support hundreds of millions&nbsp;of Apple devices are expected to begin in 2027.
MP Materials had approximately $759.16 million in cash, cash equivalents and short-term investments as of March 31.
MP Price Action: <a href="http://benzinga.com/quote/mp" target="_blank" rel="noreferrer noopener">MP Materials shares</a> closed Wednesday up 0.57% at $58.55. The stock was down 6.06% in after-hours Wednesday, trading at $55 at the time of publication, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/07/46455550/united-airlines-q2-earnings-revenue-miss-eps-beat-lowered-fy25-guidance-despite-positive-shift-in-demand-in-early-july">United Airlines Q2 Earnings: Revenue Miss, EPS Beat, Lowered FY25 Guidance Despite &#8216;Positive Shift In Demand&#8217; In Early July</a></li>
</ul>
Photo: courtesy of MP Materials.

Offerings

After-Hours Center

Movers

MP Materials Stock Is Sliding After Hours: Here's Why

WIIM

YHC stock has given up its prior loss. LQR House shares were trading lower after the company and its board were named in a lawsuit about the breach of fiduciary duty.

<h3>Gainers</h3>
<ul>
<li>Monarch Casino &amp; Resort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRI#NASDAQ">MCRI</a>) stock moved upwards by 14.6% to $100.11 during Wednesday's after-market session. The company's market cap stands at $1.6 billion. As per the press release, Q2 earnings came out today. </li>
<li>Algorhythm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIME#NASDAQ">RIME</a>) stock increased by 7.72% to $2.51. The company's market cap stands at $5.9 million. </li>
<li>Genius Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GNS#AMEX">GNS</a>) shares increased by 3.79% to $1.64. The company's market cap stands at $122.0 million. </li>
<li>Boqii Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BQ#AMEX">BQ</a>) stock moved upwards by 3.7% to $2.8. The market value of their outstanding shares is at $8.6 million. </li>
<li>Birks Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BGI#AMEX">BGI</a>) shares rose 3.49% to $0.87. The company's market cap stands at $16.4 million. </li>
<li>Lottery.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEGG#NASDAQ">SEGG</a>) stock increased by 3.38% to $1.22. The company's market cap stands at $31.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Lulus Fashion Lounge (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVLU#NASDAQ">LVLU</a>) stock declined by 8.1% to $4.32 during Wednesday's after-market session. The company's market cap stands at $14.4 million. </li>
<li>Epsium Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPSM#NASDAQ">EPSM</a>) shares declined by 6.79% to $25.0. The company's market cap stands at $325.2 million. </li>
<li>Grove Collaborative Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GROV#NYSE">GROV</a>) shares declined by 4.64% to $1.44. The market value of their outstanding shares is at $57.5 million. </li>
<li>Springview Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPHL#NASDAQ">SPHL</a>) shares fell 4.53% to $0.48. The company's market cap stands at $5.5 million. </li>
<li>Naas Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAAS#NASDAQ">NAAS</a>) stock fell 4.35% to $0.53. The market value of their outstanding shares is at $7.6 million. </li>
<li>WW International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WW#NASDAQ">WW</a>) stock fell 4.02% to $33.5. The market value of their outstanding shares is at $3.0 billion. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EPSM

GROV

LVLU

MCRI

NAAS

RIME

SEGG

SPHL

12 Consumer Discretionary Stocks Moving In Wednesday's After-Market Session

Scale AI, a San Francisco startup, recently celebrated a $14.3 billion investment from Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>). Shortly afterward, it laid off 14% of<a href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/07/46423783/why-metas-ai-edge-makes-it-the-top-ad-stock-for-2025"> its total staff.</a>
The Details: The artificial intelligence company confirmed Wednesday that it is reducing its workforce by 200 full-time employees.
Among those unscathed is Scale AI&#8217;s founder, billionaire Alexandr Wang, who Meta tapped to lead its AI efforts.
Scale AI's interim CEO, Jason Droege, who stepped into the role after Wang's departure, acknowledged in a memo to staff that the company expanded its generative AI operations too rapidly and developed unnecessary bureaucracy, according to <a href="https://www.cnbc.com/2025/07/16/scale-ai-cuts-14percent-of-workforce-after-meta-investment-hiring-of-wang.html">CNBC</a>. 
Droege emphasized that Scale AI remains financially strong and well-resourced, despite the cuts. 
Read Next: <a href="https://www.benzinga.com/markets/tech/25/07/46422009/rare-earth-royalty-meet-the-power-players-shaping-the-industry?utm_source=articleShare">Rare Earth Royalty: Meet The Power Players Shaping The Industry</a>
Droege wrote that these organizational changes are designed to help the company become more agile and better prepared to respond to evolving market demands. 
"This structure will allow us to better serve the customers we have today and win back customers that have slowed down work with us," Droege wrote in the memo.&nbsp;
Droege added that Scale AI intends to boost hiring significantly in the latter half of the year, especially in its application, enterprise and public sector divisions.
At the time of these layoffs, Scale AI employed about 1,400 people globally. Scale AI spokesperson Joe Osborne said that departing employees will receive severance packages. The company will also discontinue work with 500 contractors worldwide. 
Osborne added that the company is restructuring its data business to provide improved solutions for its generative AI customers. The plan is to invest heavily and hire in its enterprise and government AI sectors.
Why It Matters: Meanwhile, Meta has been aggressively hiring AI talent to better compete with industry rivals like OpenAI. CEO Mark Zuckerberg chose Wang to lead Meta's newly established Meta Superintelligence Labs as chief AI officer. Only a handful of Scale AI employees have joined Meta as well.
Meta also recently recruited two <a href="https://www.benzinga.com/markets/tech/25/07/46434602/mark-zuckerbergs-meta-poaches-top-openai-researchers-jason-wei-and-hyung-won-chung-for-its-superintelligence-lab-report">prominent researchers</a> from OpenAI—Jason Wei and Hyung Won Chung—to join its new superintelligence lab.&nbsp;&nbsp;
This recruitment is part of Meta's broader strategy. The Facebook parent is reportedly making compensation offers as high as $300 million over four years.
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46374434/joby-aviation-stock-goes-vertical-as-secret-massive-drone-achieves-9-hour-flight?utm_source=articleShare">Joby Aviation Stock Goes Vertical As Secret, Massive Drone Achieves 9-Hour Flight</a></li>
</ul>
Photo: Shutterstock

Large Cap

Management

Tech

Scale AI Slashes 14% Of Workforce After Meta's $14 Billion Investment

<h3>Gainers</h3>
<ul>
<li>Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) stock increased by 37.4% to $25.26 during Wednesday's after-market session. The market value of their outstanding shares is at $1.7 billion. </li>
<li>Athira Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHA#NASDAQ">ATHA</a>) shares increased by 9.34% to $0.42. The market value of their outstanding shares is at $15.4 million. </li>
<li>Pheton Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTHL#NASDAQ">PTHL</a>) stock increased by 5.96% to $22.19. The market value of their outstanding shares is at $298.8 million. </li>
<li>PDS Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDSB#NASDAQ">PDSB</a>) stock increased by 5.1% to $1.27. The market value of their outstanding shares is at $53.4 million. </li>
<li>SunLink Health Systems (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SSY#AMEX">SSY</a>) stock rose 5.0% to $1.05. The market value of their outstanding shares is at $7.0 million. </li>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) shares increased by 4.99% to $0.92. The market value of their outstanding shares is at $5.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>OKYO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKYO#NASDAQ">OKYO</a>) shares fell 11.3% to $2.6 during Wednesday's after-market session. The market value of their outstanding shares is at $102.9 million. </li>
<li>enVVeno Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNO#NASDAQ">NVNO</a>) stock decreased by 7.82% to $3.94. The market value of their outstanding shares is at $72.3 million. </li>
<li>Maze Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAZE#NASDAQ">MAZE</a>) stock fell 6.69% to $15.22. The market value of their outstanding shares is at $701.1 million. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) stock declined by 6.43% to $1.02. The market value of their outstanding shares is at $19.7 million. </li>
<li>Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) stock declined by 6.25% to $0.8. The company's market cap stands at $52.7 million. </li>
<li>HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares decreased by 6.06% to $4.5. The company's market cap stands at $9.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATHA

ATNF

HCWB

KAPA

MAZE

NVNO

OKYO

PDSB

PTHL

SRPT

12 Health Care Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>WF International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WXM#NASDAQ">WXM</a>) stock increased by 11.4% to $3.9 during Wednesday's after-market session. The market value of their outstanding shares is at $25.5 million. </li>
<li>ATIF Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBAI#NASDAQ">ZBAI</a>) stock rose 6.48% to $0.7. The market value of their outstanding shares is at $8.7 million. </li>
<li>Linkers Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNKS#NASDAQ">LNKS</a>) shares rose 5.88% to $0.55. The company's market cap stands at $7.3 million. </li>
<li>NeoVolta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOV#NASDAQ">NEOV</a>) stock moved upwards by 5.48% to $4.81. The market value of their outstanding shares is at $155.6 million. </li>
<li>AgEagle Aerial Sys (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UAVS#AMEX">UAVS</a>) stock rose 5.45% to $1.54. The company's market cap stands at $17.5 million. </li>
<li>ClearSign Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLIR#NASDAQ">CLIR</a>) stock increased by 4.87% to $0.52. The market value of their outstanding shares is at $27.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Graphjet Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTI#NASDAQ">GTI</a>) stock fell 8.7% to $0.09 during Wednesday's after-market session. The company's market cap stands at $10.7 million. </li>
<li>LanzaTech Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNZA#NASDAQ">LNZA</a>) shares decreased by 5.18% to $0.28. The company's market cap stands at $67.7 million. </li>
<li>Proto Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NYSE">PRLB</a>) stock decreased by 4.98% to $37.62. The market value of their outstanding shares is at $955.9 million. </li>
<li>Wheels Up Experience (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UP#NYSE">UP</a>) stock declined by 4.14% to $1.39. The company's market cap stands at $957.4 million. </li>
<li>Aeries Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AERT#NASDAQ">AERT</a>) stock decreased by 3.71% to $1.04. The company's market cap stands at $48.5 million. </li>
<li>Professional Diversity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPDN#NASDAQ">IPDN</a>) stock decreased by 3.51% to $2.48. The market value of their outstanding shares is at $5.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Advanced Environmental Recycling Technologies

AERT

CLIR

IPDN

LNKS

LNZA

NEOV

PRLB

UAVS

ZBAI

12 Industrials Stocks Moving In Wednesday's After-Market Session

Dollar General CFO Kelly M. Dilts Resigns Effective August 28

<h3>Gainers</h3>
<ul>
<li>Locafy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCFY#NASDAQ">LCFY</a>) shares increased by 14.2% to $5.15 during Wednesday's after-market session. The company's market cap stands at $5.6 million. </li>
<li>Mobilicom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOB#NASDAQ">MOB</a>) stock rose 6.3% to $3.37. The company's market cap stands at $24.1 million. </li>
<li>KVH Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KVHI#NASDAQ">KVHI</a>) shares moved upwards by 5.86% to $5.6. The company's market cap stands at $102.7 million. </li>
<li>Maris Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEK#NASDAQ">MTEK</a>) stock moved upwards by 4.73% to $3.54. The market value of their outstanding shares is at $26.5 million. </li>
<li>Kopin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOPN#NASDAQ">KOPN</a>) shares rose 4.63% to $2.03. The market value of their outstanding shares is at $262.8 million. </li>
<li>Bit Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTBT#NASDAQ">BTBT</a>) shares moved upwards by 4.58% to $4.11. The company's market cap stands at $978.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>SMX (Security Matters) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMX#NASDAQ">SMX</a>) shares decreased by 16.6% to $1.51 during Wednesday's after-market session. The company's market cap stands at $3.9 million. </li>
<li>Soluna Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNH#NASDAQ">SLNH</a>) stock decreased by 8.78% to $0.58. The company's market cap stands at $13.9 million. </li>
<li>Glimpse Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAR#NASDAQ">VRAR</a>) shares declined by 4.84% to $1.37. The market value of their outstanding shares is at $31.4 million. </li>
<li>My Size (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYSZ#NASDAQ">MYSZ</a>) stock declined by 4.66% to $1.23. The market value of their outstanding shares is at $3.8 million. </li>
<li>CLPS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLPS#NASDAQ">CLPS</a>) shares fell 4.04% to $0.96. The company's market cap stands at $26.1 million. </li>
<li>Alpha Modus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMOD#NASDAQ">AMOD</a>) shares declined by 3.88% to $1.2. The market value of their outstanding shares is at $16.7 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMOD

BTBT

CLPS

KOPN

KVHI

LCFY

MTEK

MYSZ

SLNH

VRAR

12 Information Technology Stocks Moving In Wednesday's After-Market Session

Ratings for Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $143.2, a high estimate of $150.00, and a low estimate of $133.00. This current average reflects an increase of 0.56% from the previous average price target of $142.40. 
<img src="https://www.benzinga.com/files/images/story/2025/1752699927_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Addus HomeCare. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$150.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$150.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Tao Qiu</td>
<td>Macquarie</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$133.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Tao Qiu</td>
<td>Macquarie</td>
<td>Raises</td>
<td>Outperform</td>
<td>$133.00</td>
<td>$129.00</td>
</tr>
<tr>
<td>Nicholas Jones</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$150.00</td>
<td>$150.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Addus HomeCare. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Addus HomeCare compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Addus HomeCare's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ADUS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Addus HomeCare analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Addus HomeCare</h2>
Addus HomeCare Corp is engaged in the provision of in-home personal care services. It operates through the segments such as Personal care segment, which is a key revenue driver, provides non-medical assistance with activities of daily living, primarily to persons who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and their families. Its Home health segment provides services that are primarily medical in nature to those individuals who may require assistance during an illness or after surgery.
<h3>Breaking Down Addus HomeCare's Financial Performance</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Addus HomeCare's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 20.29%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 6.29%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.16%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Addus HomeCare's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.51% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.25, Addus HomeCare adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

ADUS

Assessing Addus HomeCare: Insights From 5 Financial Analysts

TABER, ALBERTA, July 16, 2025 (GLOBE NEWSWIRE) -- FLEXIBLE SOLUTIONS INTERNATIONAL, INC. (NYSE-AMERICAN: FSI),&nbsp;is the developer and manufacturer of biodegradable polymers for oil extraction, detergent ingredients and water treatment as well as crop nutrient availability chemistry. Flexible Solutions also manufactures biodegradable and environmentally safe water and energy conservation technologies. In addition, FSI is increasing its presense in the food and nutrition supplement manufacturing markets. Today the Company announces second quarter (Q2), 2025 revenue.
Sales were up in Q2, 2025 compared to Q2, 2024. Flexible Solutions' top line revenue increased to $11.212 million (Q2, 2025) from $10.529 million (Q2, 2024) to), up approximately 6.5% year over year.
Mr. Dan O'Brien, CEO, comments, "The $2.5 million payment for food grade product development moved our Q2 revenue from poor to good. We saw weakness from several historic customers in the quarter most likely related to general business conditions, tariff uncertainty and inventory reduction." Mr. O'Brien continues, "Volatility in our base business reinforces our decision to emphasize food grade operations but, it does not change our opinion that the second half of 2025 will see growth unless economic conditions decay further."
Complete financial results will be available after market close on Thursday, August 14, 2025, concurrent with the Company's SEC second quarter filings. A conference call will be scheduled for 8:00 am Pacific Time, 11:00 am Eastern Time, the following business day, Friday, August 15, 2025. See the FSI August 14, 2025 financials news release for the dial in numbers.

Flexible Solutions International Announces Q2 2025 Revenue; Top Line Revenue Increased From $10.529 Million To $11.212M, Up ~6.5% Year Over Year

In the last three months, 12 analysts have published ratings on MasTec (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">9</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $181.67, along with a high estimate of $210.00 and a low estimate of $152.00. This current average has increased by 14.76% from the previous average price target of $158.30. 
<img src="https://www.benzinga.com/files/images/story/2025/1752699855_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive MasTec. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Heath</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$196.00</td>
<td>$171.00</td>
</tr>
<tr>
<td>Philip Shen</td>
<td>Roth Capital</td>
<td>Announces</td>
<td>Buy</td>
<td>$210.00</td>
<td>-</td>
</tr>
<tr>
<td>Ati Modak</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$195.00</td>
<td>$156.00</td>
</tr>
<tr>
<td>Brian Brophy</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$181.00</td>
<td>$171.00</td>
</tr>
<tr>
<td>Julien Dumoulin-Smith</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$188.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$170.00</td>
<td>$152.00</td>
</tr>
<tr>
<td>Kashy Harrison</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$175.00</td>
<td>$134.00</td>
</tr>
<tr>
<td>Brian Brophy</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$171.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$184.00</td>
<td>$154.00</td>
</tr>
<tr>
<td>Sangita Jain</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$163.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Joseph Osha</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$195.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$152.00</td>
<td>$167.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to MasTec. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of MasTec compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for MasTec's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of MasTec's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MTZ/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on MasTec analyst ratings.</a>
<h2>About MasTec</h2>
MasTec is a leading infrastructure construction company operating mainly in North America across a range of industries. The company's primary activities include engineering, building, installing, maintaining, and upgrading communications, oil and gas, utility, renewable energy, and other infrastructure. MasTec reports its results under five segments: communications; clean energy and infrastructure; oil and gas; power delivery; and other.
<h3>Financial Insights: MasTec</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: MasTec displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 5.99%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: MasTec's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 0.35%, the company may face hurdles in effective cost management.
Return on Equity (ROE): MasTec's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 0.34%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): MasTec's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.11%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: MasTec's debt-to-equity ratio surpasses industry norms, standing at 0.91. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into MasTec Stock: Analyst Perspectives (12 Ratings)

Ratings for Jacobs Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/J#NYSE">J</a>) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $150.6, a high estimate of $155.00, and a low estimate of $141.00. Surpassing the previous average price target of $149.25, the current average has increased by 0.9%.
<img src="https://www.benzinga.com/files/images/story/2025/1752699842_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of Jacobs Solutions by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sangita Jain</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$155.00</td>
<td>-</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$141.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Steven Fisher</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$152.00</td>
<td>$154.00</td>
</tr>
<tr>
<td>Sabahat Khan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$154.00</td>
<td>$152.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$151.00</td>
<td>$161.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Jacobs Solutions. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Jacobs Solutions compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Jacobs Solutions's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Jacobs Solutions's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/J/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Jacobs Solutions analyst ratings.</a>
<h2>All You Need to Know About Jacobs Solutions</h2>
Jacobs Solutions is a global provider of engineering, design, procurement, construction, and maintenance services as well as cyber engineering and security solutions. The firm serves industrial, commercial, and government clients in a wide variety of sectors, including water, transportation, healthcare, technology, and chemicals. Jacobs Solutions employs approximately 60,000 workers. The company generated $11.5 billion in revenue in fiscal 2024.
<h3>A Deep Dive into Jacobs Solutions's Financials</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Over the 3M period, Jacobs Solutions showcased positive performance, achieving a revenue growth rate of 2.22% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Jacobs Solutions's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 0.24%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 0.17%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.06%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Jacobs Solutions's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.81.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Jacobs Solutions Stock: Analyst Perspectives (5 Ratings)

During the last three months, 6 analysts shared their evaluations of Ares Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCC#NASDAQ">ARCC</a>), revealing diverse outlooks from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $22.08, a high estimate of $23.00, and a low estimate of $21.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 2.95%. 
<img src="https://www.benzinga.com/files/images/story/2025/1752699806_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A clear picture of Ares Capital's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Doug Harter</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$22.50</td>
<td>$22.00</td>
</tr>
<tr>
<td>Finian O'Shea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$22.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Kenneth Lee</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$23.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Finian O'Shea</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$21.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Finian O'Shea</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$22.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Melissa Wedel</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$22.00</td>
<td>$24.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ares Capital. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Ares Capital compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Ares Capital's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Ares Capital's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ARCC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Ares Capital analyst ratings.</a>
<h2>Unveiling the Story Behind Ares Capital</h2>
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing primarily in first lien senior secured loans (including unitranche loans, which are loans that combine both senior and subordinated debt, generally in a first lien position) and second lien senior secured loans. In addition to senior secured loans, the company also invests in subordinated loans and preferred equity, it also makes common equity investments.
<h3>Key Indicators: Ares Capital's Financial Health</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Ares Capital's revenue growth over a period of 3M has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately -44.65%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: Ares Capital's net margin excels beyond industry benchmarks, reaching 87.96%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Ares Capital's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 1.78%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Ares Capital's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.85%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.02.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARCC

The Analyst Verdict: Ares Capital In The Eyes Of 6 Experts

Comments

Bristol-Myers Squibb

Bristol-Myers Squibb (BMYMP) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL